Skip to main content
SpringerLink
Log in

LEADER-Studie: 22 %ige Senkung der kardiovaskulären Mortalität

LEADER study: 22 % reduction in cardiovascular mortality

  • Journal Club
  • Published:
Der Kardiologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB, LEADER Steering Committee, LEADER Trial Investigators (2016) Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. doi:10.1056/NEJMoa1603827

    Google Scholar 

  2. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, EMPA-REG OUTCOME Investigators (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–2128

    Article  CAS  PubMed  Google Scholar 

  3. Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, Guarino PD, Lovejoy AM, Peduzzi PN, Conwit R, Brass LM, Schwartz GG, Adams HP Jr, Berger L, Carolei A, Clark W, Coull B, Ford GA, Kleindorfer D, O’Leary JR, Parsons MW, Ringleb P, Sen S, Spence JD, Tanne D, Wang D, Winder TR, IRIS Trial Investigators (2016) Pioglitazone after Ischemic stroke or transient ischemic attack. New Engl J Med 374:1321–1331

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Ussher JR, Drucker DJ (2014) Cardiovascular actions of Incretin-based therapies. Circ Res 114:1788–1803

    Article  CAS  PubMed  Google Scholar 

  5. Li L, Li S, Lin J, Vandvik PO, Zhang L, Shen J, Bala MM, Sohani ZN, Won E, Buss JW, Ebrahim S, Malaga G, Rios LP, Wang Y, Chen Q, Guyatt GH, Sun X (2016) Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies. BMJ 352:i610

    Article  PubMed  PubMed Central  Google Scholar 

  6. Chalmer T, Almdal TP, Vilsboll T, Knop FK (2015) Adverse drug reactions associated wih the use of liraglutide in patients with type 2 diabetes – focus on pancreatits and pancreas cancer. Expert Opin Drug Saf 14:171–180

    Article  CAS  PubMed  Google Scholar 

  7. Jensen TM, Sha K, Steinberg WM (2015) Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care 38:1058–1066

    Article  CAS  PubMed  Google Scholar 

  8. Tseng CH, Lee KY, Tseng FH (2015) An updated review on cancer risk associated with incretin mimetics and enhancers. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 33:67–124

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Knappschaftskrankenhaus, Klinikum Vest GmbH, Dorstener Str.151, 45657, Recklinghausen, Deutschland

    I. Vardarli EU M.Sc. &  C. Özcelik

Authors
  1. I. Vardarli EU M.Sc.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Özcelik
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to I. Vardarli EU M.Sc..

Ethics declarations

Interessenkonflikt

I. Vardarli und C. Özcelik geben an, dass kein Interessenkonflikt besteht.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vardarli, I., Özcelik, C. LEADER-Studie: 22 %ige Senkung der kardiovaskulären Mortalität. Kardiologe 10, 339–340 (2016). https://doi.org/10.1007/s12181-016-0089-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12181-016-0089-x

Search

Navigation